Cellecta, Inc. was founded in April of 2006 by one of the chief scientists from Clontech Laboratories. The contract research company was borne out of the need for higher-quality, more advanced shRNA and peptide libraries. Our mission is to develop advanced high-throughput (HT) genetic screen technologies and their applications for the discovery and functional characterization of novel therapeutic targets and drugs.
Cellecta’s primary aim is to develop advanced high-throughput RNAi and peptide technologies and their applications for the discovery and functional characterization of novel therapeutic targets and drugs. We offer highly customized contract research services using advanced lentiviral technology, including custom focused and genome-wide pooled lentiviral shRNA libraries, for any set of genes in any lentivector; RNAi genetic screens with pooled lentiviral shRNA libraries; reporter cell line development for genetic screens; bioinformatic data analysis for RNAi genetic screens; custom stable cDNA overproducer or shRNA expression knockdown cell lines; cell-based HT screening for bioactive peptides with pooled peptide libraries; and rational directed evolution for peptide lead optimization. With more than 7 years of experience in HT functional screening, our scientists have developed the most advanced technology available in collaboration with opinion leaders and with funding from 10 NIH SBIR grants.
Cellecta is headed by an experienced management and product development team with a good product development track record, a network of outside scientific collaborators, and prior experience in start-up company operations. Located in Mountain View, CA in the heart of Silicon Valley, the company resides in the "Biotech Bay" area near some of the most well-known research biotech companies and life science institutes including Affymetrix, Genentech, Stanford University, and the University of California, San Francisco.
Although a small private company, Cellecta is connected to a large network of collaborators, consultants, and colleagues, vastly improving its knowledge base in the research field. Cellecta has partnered with a multitude of scientists and institutions, including the Roswell Park Cancer Institute, Fred Hutchinson Cancer Research Center (FHCRC), The Scripps Research Institute (TSRI), Cleveland Biolabs, Harvard School of Public Health, Tufts University, and Health Research, Inc. If you are interested in collaborating or investing in Cellecta, please contact us at firstname.lastname@example.org or email@example.com.